Breaking News

HPNE Unveils HPConnexx

A single-use assembly solution suitable for all areas of biopharmaceutical processing from discovery to fill-finish.

By: Contract Pharma

Contract Pharma Staff

To help meet the increasing demand for single-use assembly solutions in the biopharma industry, High Purity New England (HPNE), a supplier of biopharma equipment and process solutions for the biopharma industry, has created HPConnexx, a single-use assembly solution suitable for all areas of biopharmaceutical processing from discovery to fill-finish. 
 
Manufactured in an ISO 7 Cleanroom, the solution is unique in that it can utilize other vendors’ components and can be implemented directly into any process. There is no minimum order size for an assembly and lead times can be as short as weeks, compared to the industry standard of months. As part of the service, the team at HPNE also provide full integrity and validation testing on its single-use assemblies.
 
“As the biopharma industry continues to grow and develop, pipelines fill with promising, smaller-volume therapies. It is essential that businesses throughout the sector get the support they need to get their drugs to market,” said Mark Sitcoske, CEO and founder at HPNE. “Single-use technologies can reduce the costs associated with infrastructure, save time by decreasing the need for cleaning and validation and negate the risk of cross contamination. However, not all single-use solutions are fully customizable, and many have lengthy lead times for installation. That is why we developed HPConnexx.”
 
“The solution, and the support we deliver around it, is truly unique as it can be customized in any way the customer requires. It can be connected to any existing process at any scale and utilize any components regardless of inter-company connectivity,” he added.
 
HPNE specializes in single-use solutions used in pharmaceutical research and development, process development and full-scale production activities. The company is currently providing flexible, single-use solutions to companies developing vaccines in the fight to combat COVID-19.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters